1. Home
  2. MIRM vs RVLV Comparison

MIRM vs RVLV Comparison

Compare MIRM & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$80.29

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Logo Revolve Group Inc.

RVLV

Revolve Group Inc.

HOLD

Current Price

$29.78

Market Cap

2.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
RVLV
Founded
2018
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Catalog/Specialty Distribution
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
2.1B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
MIRM
RVLV
Price
$80.29
$29.78
Analyst Decision
Strong Buy
Buy
Analyst Count
11
13
Target Price
$92.45
$26.42
AVG Volume (30 Days)
818.0K
1.0M
Earning Date
11-04-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
35.78
EPS
N/A
0.78
Revenue
$471,794,000.00
$1,195,039,000.00
Revenue This Year
$53.78
$8.95
Revenue Next Year
$19.91
$6.42
P/E Ratio
N/A
$38.50
Revenue Growth
53.66
9.24
52 Week Low
$36.88
$16.80
52 Week High
$82.58
$34.39

Technical Indicators

Market Signals
Indicator
MIRM
RVLV
Relative Strength Index (RSI) 69.54 71.76
Support Level $63.23 $28.95
Resistance Level $82.58 $29.96
Average True Range (ATR) 3.70 1.11
MACD 1.73 0.10
Stochastic Oscillator 90.54 93.76

Price Performance

Historical Comparison
MIRM
RVLV

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About RVLV Revolve Group Inc.

Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.

Share on Social Networks: